NCT04708587

Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 900 (estimated)
• Sponsor: Yonsei University · Academic / Other
• Sex: All
• Age: 19 Years – 84 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this prospective randomized clinical trial is to compare the clinical outcomes according to the duration of aspirin and clopidogrel or prasugrel with dual anti-platelet therapy after percutaneous coronary intervention in patients with advanced chronic kidney disease using a new generation drug eluting stents.

Detailed description

Prospective, open label, multicenter randomized clinical trial

Conditions

• Chronic Kidney Diseases

Interventions

Type	Name	Description
DRUG	dual anti-platelet therapy at least 6 months	Patients enrolled in dual antiplatelets at least 6 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for at least 6 months after randomization. Clopidogrel or prasugrel should be maintained after 6 months.
DRUG	dual anti-platelet therapy 3months or less	Patient enrolled in the dual antiplatelet therapy less than 3 months arm would be administered with aspirin 100mg plus clopidogrel 75mg or prasugrel 10mg once daily for less than 3 months after randomization. After 3 months clopidogrel or prasugrel should be maintained.

Timeline

• Start date: 2021-03-23
• Primary completion: 2027-03-13
• Completion: 2028-03-13
• First posted: 2021-01-14
• Last updated: 2026-01-21

Locations

1 site across 1 country: South Korea